Correlation Between Iovance Biotherapeutics and Procaps Group

Can any of the company-specific risk be diversified away by investing in both Iovance Biotherapeutics and Procaps Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Iovance Biotherapeutics and Procaps Group into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Iovance Biotherapeutics and Procaps Group SA, you can compare the effects of market volatilities on Iovance Biotherapeutics and Procaps Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Iovance Biotherapeutics with a short position of Procaps Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of Iovance Biotherapeutics and Procaps Group.

Diversification Opportunities for Iovance Biotherapeutics and Procaps Group

-0.17

Correlation Coefficient

Iovance Biotherapeutics  Procaps Group

Good diversification

The 3 months correlation between Iovance and Procaps is -0.17. Overlapping area represents the amount of risk that can be diversified away by holding Iovance Biotherapeutics and Procaps Group SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Procaps Group SA and Iovance Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Iovance Biotherapeutics are associated (or correlated) with Procaps Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Procaps Group SA has no effect on the direction of Iovance Biotherapeutics i.e., Iovance Biotherapeutics and Procaps Group go up and down completely randomly.

Pair Corralation between Iovance Biotherapeutics and Procaps Group

Given the investment horizon of 90 days Iovance Biotherapeutics is expected to under-perform the Procaps Group. But the stock apears to be less risky and, when comparing its historical volatility, Iovance Biotherapeutics is 4.34 times less risky than Procaps Group. The stock trades about -0.2 of its potential returns per unit of risk. The Procaps Group SA is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest  111.00  in Procaps Group SA on October 22, 2024 and sell it today you would earn a total of  60.00  from holding Procaps Group SA or generate 54.05% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Iovance Biotherapeutics  vs.  Procaps Group SA

Iovance Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Iovance Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Procaps Group SA

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Procaps Group SA are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Procaps Group exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Iovance Biotherapeutics and Procaps Group

The main advantage of trading using opposite Iovance Biotherapeutics and Procaps Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Iovance Biotherapeutics position performs unexpectedly, Procaps Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Procaps Group will offset losses from the drop in Procaps Group's long position.

The idea behind Iovance Biotherapeutics and Procaps Group SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.